Esophageal gastrointestinal stromal tumors: a literature review
Gastrointestinal Stromal Tumor · 2023
DOI: 10.21037/gist-21-18 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastrointestinal Stromal Tumor, 2023. Verfasst von Carlo Alberto De Pasqual und 3 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref).
Abstract (Originalsprache)
Background and Objective: Gastrointestinal stromal tumors (GISTs) account for less than 1% of digestive tract tumors. The most common location of these tumors is the stomach, while the esophageal location is estimated to be between 0.7–5% of all GISTs, which explains the lack of specific guidelines and randomized trials. The objective of this review is to develop a revision of literature about clinicopathological features, diagnostic and treatment management.
Methods
We searched PubMed, Embase, Google Scholar and MEDLINE databases from 1998 to 2022 by using the keywords: “Esophageal gastrointestinal stromal tumor”, “GIST”, “GIST treatment”, “GIST epidemiology”, “GIST surgical treatment”, “esophageal GIST management”, “imatinib”, “GIST clinicopathologic features”. Additional literature was searched manually from references of related articles. Key Content and Findings: GISTs arising from the interstitial cells of Cajal (ICC), are CD117 positive and are characterized by mutations in the c-kit genes or mutations of the platelet-derived growth factor receptor alpha. Their diagnosis is often challenging and it is difficult to distinguish themselves from other subepithelial lesions that arise from the esophagus, such as leiomyomas and leiomyosarcomas. The endoscopic ultrasound plays an important role in the identification of GISTs but the immunopathological assessment via fine needle aspiration biopsy during endoscopic ultrasound is substantial for the precise diagnosis. These tumors are potentially malignant and their goal standard treatment is based on radical surgery. Endoscopic management has also been described for smaller and low risk GISTs. Chemotherapy is based on tyrosine kinase inhibitors (TKIs) which have been described in metastatic, adjuvant and neoadjuvant settings.
Conclusions
Esophageal GISTs are a rare entity and their optimal management has not been yet defined and more data based on prospective studies or clinical trials are necessary.
Zitieren
APA
Pasqual, C. A. D., Hetoja, S., Gervasi, M. C., & Manzoni, G. D. (2023). Esophageal gastrointestinal stromal tumors: a literature review. Gastrointestinal Stromal Tumor. https://doi.org/10.21037/gist-21-18
Vancouver
Pasqual CAD, Hetoja S, Gervasi MC, Manzoni GD. Esophageal gastrointestinal stromal tumors: a literature review. Gastrointestinal Stromal Tumor. 2023. doi:10.21037/gist-21-18
BibTeX
@article{Pasqual2023,
author = {Pasqual, Carlo Alberto De and Hetoja, Selma and Gervasi, Maria Clelia and Manzoni, Giovanni de},
title = {Esophageal gastrointestinal stromal tumors: a literature review},
journal = {Gastrointestinal Stromal Tumor},
year = {2023},
doi = {10.21037/gist-21-18}
}
EUVIMED